open access

Vol 10, No 4 (2014)
Review paper
Published online: 2014-08-29
Get Citation

Regorafenib — the efficacy and safety in the treatment of the advanced gastrointestinal stromal tumors after failure in treatment with imatynib and sorafenib — the summary and a disscussion of the phase III trial

Joanna Stępniak, Piotr Rutkowski
Onkol. Prak. Klin 2014;10(4):192-195.

open access

Vol 10, No 4 (2014)
REVIEW ARTICLES
Published online: 2014-08-29

Abstract

The article discusses the international, multicentre, randomised, placebo-controlled phase III trial, published in 2012, performed in patients with metastatic or unresectable gastrointestinal stromal tumor progressing after the failure of at least imatinib and sunitinib. The trial was conducted in order to assess the efficacy and safety of regorafenib — the newest, oral, multiknase inhibitor, and resulted in the registration of that drug as a third line treatment in patients with drug-resistant GIST. The article focuses on the difficulties related to the treatment of advanced or metastatic GIST, summarizing the newest research and clinical implications of the results.

Abstract

The article discusses the international, multicentre, randomised, placebo-controlled phase III trial, published in 2012, performed in patients with metastatic or unresectable gastrointestinal stromal tumor progressing after the failure of at least imatinib and sunitinib. The trial was conducted in order to assess the efficacy and safety of regorafenib — the newest, oral, multiknase inhibitor, and resulted in the registration of that drug as a third line treatment in patients with drug-resistant GIST. The article focuses on the difficulties related to the treatment of advanced or metastatic GIST, summarizing the newest research and clinical implications of the results.

Get Citation

Keywords

gastrointestinal stromal tumor, GIST, regorafenib, imatinib, sunitynib, phase III trial

About this article
Title

Regorafenib — the efficacy and safety in the treatment of the advanced gastrointestinal stromal tumors after failure in treatment with imatynib and sorafenib — the summary and a disscussion of the phase III trial

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 4 (2014)

Article type

Review paper

Pages

192-195

Published online

2014-08-29

Bibliographic record

Onkol. Prak. Klin 2014;10(4):192-195.

Keywords

gastrointestinal stromal tumor
GIST
regorafenib
imatinib
sunitynib
phase III trial

Authors

Joanna Stępniak
Piotr Rutkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl